JNJ-64619178
Sponsors
Janssen-Cilag International NV, Yoshinari Nozomi, Janssen Research & Development, LLC
Conditions
Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLeukemia, Myeloid, Acute
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-HodgkinLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsNon-Hodgkin LymphomaNon-Hodgkin lymphoma and chronic lymphocytic leukemia
Cancer
Phase 1
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
CompletedNCT03573310
Start: 2018-07-13End: 2025-09-25Updated: 2025-12-18
A rollover study for continued study treatment and ongoing safety monitoring
RecruitingISRCTN87946208
Start: 2024-12-31Target: 77Updated: 2025-03-31
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Enrolling by invitationNCT06788509
Start: 2024-12-30End: 2028-10-30Target: 120Updated: 2026-07-06
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Active, not recruitingJPRN-jRCT2041240191
Start: 2025-02-19Target: 80Updated: 2026-06-29